A B S T R A C T
Background. Viral infections can trigger chronic kidney disease (CKD) and the urine virome may inform risk. The Natural History of APOL1-Associated Nephropathy Study (NHAANS) reported that urine JC polyomavirus (JCPyV) associated with a lower risk of APOL1-associated nephropathy in African Americans. Herein, association was assessed between urine JCPyV with CKD in African Americans independent from the APOL1 genotype. Methods. Quantitative polymerase chain reaction was performed for urinary detection of JCPyV and BK polyoma virus (BKPyV) in 200 newly recruited nondiabetic African Americans. A combined analysis was performed in these individuals plus 300 NHAANS participants. Results. In the 200 new participants, urine JCPyV was present in 8.8% of CKD cases and 45.8% of nonnephropathy controls (P ¼ 3.0 Â 10
À8
). In those with APOL1 renal-risk genotypes, JCPyV was detected in 5.1% of cases and 40.0% of controls (P ¼ 0.0002). In those lacking APOL1 renal-risk genotypes, JCPyV was detected in 12.2% of cases and 48.8% of controls (P ¼ 8.5 Â 10
À5
). BKPyV was detected in 1.3% of cases and 0.8% of controls (P ¼ 0.77). In a combined analysis with 300 NHAANS participants (n ¼ 500), individuals with urine JCPyV had a 63% lower risk of CKD compared with those without urine JCPyV (odds ratio 0.37; P ¼ 4.6 Â 10
À6
). RNA fluorescence in situ hybridization confirmed the presence of JCPyV genomic DNA and JCPyV messenger RNA (mRNA) in nondiseased kidney. Conclusions. Inverse relationships exist between JCPyV viruria and non-diabetic CKD. Future studies should determine whether renal inflammation associated with CKD is less permissive for JCPyV reactivation/replication or whether JCPyV is a marker of reduced host immune responsiveness that diminishes immune pathologic contributions to CKD.
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I N T R O D U C T I O N
Apolipoprotein L1 gene (APOL1) G1 and G2 renal-risk variants contribute to $70% of nondiabetic end-stage kidney disease (ESKD) cases in African Americans [1] [2] [3] [4] [5] [6] [7] . A potential mechanism for chronic kidney disease (CKD) could be enhancement of susceptibility to nephropathic viruses related to these variants [8] . Viral infections are known to initiate kidney disease. Human immunodeficiency virus (HIV) infection often produces glomerular inflammation with the development of HIV-associated nephropathy (HIVAN) and other kidney disease entities [4, [9] [10] [11] . Other viruses, including hepatitis B, hepatitis C and acute parvovirus B19 infection, have also been implicated in CKD [12] [13] [14] . Successful treatment of HIV, hepatitis B and hepatitis C slows the progression of nephropathy [15] . Thus we originally hypothesized that kidney infection with viruses that share the properties of HIV by demonstrating lymphotropism [e.g. cytomegalovirus (CMV) and human herpes virus 6 (HHV6)] or that maintain renal reservoirs of infection [e.g. JC polyomavirus (JCPyV) and BK polyomavirus (BKPyV)] would be more prevalent in individuals with APOL1 risk alleles [16, 17] .
However, rather than finding virus-associated risk for CKD, mounting evidence supports a nephroprotective relationship between urine JCPyV and kidney disease. In 2011, Pires et al. [18] reported significantly higher rates of urine JCPyV in healthy Brazilian controls lacking CKD compared to cases with ESKD on hemodialysis. Since these cases had severe kidney disease on dialysis, it was unclear whether this finding reflected the loss of nephron mass with diminished numbers of cells in which the virus could replicate. We therefore analyzed the relationship between urine JCPyV with genetic risk for APOL1-associated nephropathy in African Americans with mild kidney disease from the Natural History of APOL1-Associated Nephropathy Study (NHAANS) [16, 17] . In that report, close relatives of African Americans with nondiabetic ESKD who had high-risk APOL1 genotypes had significantly lower rates of kidney disease in the presence versus absence of urine JCPyV.
The present analyses were performed to extend our understanding of the protective association of urine JCPyV with nondiabetic kidney disease in African Americans; both non-APOL1 and APOL1-associated forms of CKD were evaluated. A new US-Israel Binational Science Foundation (BSF) sample set was recruited to examine cases with moderate CKD, irrespective of family history of ESKD. Analyses assessed whether the protective association of JCPyV viruria from CKD was independent from the APOL1 genotype in African Americans who lack diabetes.
M A T E R I A L S A N D M E T H O D S
US-Israel BSF study population Self-described and unrelated African Americans with nondiabetic etiologies of CKD (cases) were recruited based on their estimated glomerular filtration rate (eGFR) computed using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and a spot urine protein:creatinine ratio (UPCR). Cases with Stages 1-5 CKD (prior to initiation of dialysis) were identified in the Wake Forest School of Medicine (WFSM) Nephrology Clinic (Winston-Salem, NC, USA). Cases with Stage 5 CKD on hemodialysis with dialysis vintage <6 months were identified in Wake Forest Outpatient Dialysis Centers in northwestern North Carolina; an eGFR of 5 mL/min/1.73 m 2 was applied to these participants. Exclusion criteria included individuals who had received immunosuppressive therapy, had a prior or current kidney transplant or received renal replacement therapy for !6 months. Controls were self-described, unrelated African Americans recruited from the same geographic region in assisted living complexes or WFSM Internal Medicine clinics. Based on the lack of association between age and urine JCPyV in the prior NHAANS report (b ¼ 1.7, P ¼ 0.21 adjusting for sex, presence of CKD and APOL1 genotype) [16, 17] , controls were selected to be !55 years of age to minimize the risk of future CKD. Controls had an eGFR >90 mL/min/1.73 m 2 and UPCR <250 mg/g. CKD cases for viral analysis were selected by balancing between those with mild and severe kidney disease to mitigate potential omissions due to the effects of reduced nephron mass or urinary excretion on detectable viral shedding. All participants provided written informed consent and the study was approved by the WFSM Institutional Review Board. None of the participants were included in prior published reports [16, 17] . The USIsrael BSF and Novartis Institutes for BioMedical Research cosponsored this project. Neither sponsor had a role in protocol development, participant recruitment or sample selection in this investigator-initiated project. Novartis performed quantitative polymerase chain reaction (qPCR) for viral detection in urine without knowledge of case-control status or APOL1 genotype.
To improve the power to assess effects of JC viruria on the risk of nondiabetic CKD based on APOL1 renal-risk genotypes, a subsequent joint analysis was performed combining the 200 newly recruited participants with 300 previously reported NHAANS participants who underwent qPCR in urine for BKPyV and JCPyV [16, 19] . NHAANS participants were firstdegree relatives of African Americans with nondiabetic ESKD; their recruitment methods and demographic characteristics have been reported [16, 19] . Of the 300 NHAANS participants, 130 had two APOL1 renal-risk alleles. Of these, 61.5% were female and the median age was 49 years. Among the remaining 170 NHAANS participants with fewer than two APOL1 risk alleles, 57.7% were female and the median age was 55 years. Figure 1 displays the analyses and study participants.
Sample processing and APOL1 genotyping
Participant's urine and blood were processed on the date of collection. A minimum of 12 mL of urine, 2 mL of dipotassium ethylenediamine tetraacetic acid (K2EDTA) plasma and 2 mL of peripheral blood mononuclear cells (PBMCs) in TRIzol (Ambion, Carlsbad, CA, USA) were collected. Genomic DNA was extracted from peripheral blood using PureGene (Gentra Systems, Minneapolis, MN, USA) based on the manufacturer's instructions. Urine specimens were processed by swirling to mix and aliquots were prepared in nuclease-free freezer vials. Plasma and PBMC specimens were prepared by centrifugation of K2EDTA blood tubes at 800g for 15 min (brake off) in Leucosep tubes (Greiner-Bio-One North America, Monroe, NC, USA) preloaded with Ficoll-Paque PLUS density gradient (GE Healthcare Life Sciences, Pittsburgh, PA, USA). The plasma layer was transferred to nuclease-free freezer vials, the PBMC layer washed with Dulbecco's phosphate-buffered saline (Lonza, Walkersville, MD, USA) and cells were counted and resuspended in TRIzol at 1 Â 10 6 cells per nuclease-free freezer vial. Aliquots of urine, plasma and PBMCs were immediately snap frozen in liquid nitrogen and transferred to À80 C until shipped frozen on dry ice to Novartis for viral detection analysis. Frozen urine samples were stored for 1-30 months and thawed only immediately prior to analysis.
Two single-nucleotide polymorphisms in the APOL1 G1 nephropathy risk allele (rs73885319, rs60910145) and an indel for the G2 risk allele (rs71785313) were genotyped using a custom array designed at the WFSM Center of Genomics and Personalized Medicine on the Sequenom platform, as reported [20] .
Urine DNA extraction
Standard phenol-chloroform extraction was applied to isolate DNA from urine samples for next-generation sequencing analysis. Briefly, 300 mL aliquots of thawed raw urine specimens were mixed with 300 mL of 2X Proteinase K buffer (final concentration in 600 mL reaction mix ¼ 100 mM NaCl, 10 mM Tris-Cl pH 8.0, 1 mM ethylenediamine tetraacetic acid [EDTA] pH 8.0, 0.5% sodium dodecyl sulfate) and incubated with 20 mg Proteinase K (20 mg/mL Proteinase K solution; Thermo Fisher, Waltham, MA, USA, product number 2548) for 1 h at 50 C. Samples were cooled briefly to room temperature and incubated for 5 min with an equal volume (600 mL) of UltraPure phenol:chloroform:isoamyl alcohol (25:24:1 v/v solution; Thermo Fisher, product number 15593-049) then centrifuged at room temperature for 5 min at 12 000g. The aqueous phase of each sample was isolated and back-extracted with an equal volume of chloroform solution (high-performance liquid chromatography grade chloroform; Sigma-Aldrich, St. Louis, MO, USA, product number 650498) and centrifuged at room temperature for 5 min at 12 000g. The DNA within the aqueous phase was concentrated via standard ethanol precipitation by addition of 0.1 volumes of 3 M NaOAc pH 5.5, 30 mg GlycoBlue carrier [15 mg/mL solution (Thermo Fisher, product number 9515) and 2.5 volumes of 100% ethanol) followed by centrifugation at 4 C for 30 min at 21 000g. The resulting DNA pellets were washed twice with room temperature 70% ethanol, air dried for 5 min at room temperature and resuspended in 60 mL of nuclease-free water (Thermo Fisher, product number AM9939). QIAamp MinElute Media reagents (Qiagen, Germantown, MD, USA, product number 1025106) were used to extract DNA from an additional 250-mL aliquot of freshly thawed urine specimens for subsequent directed JCPyV and BKPyV qPCR assays. Extractions were performed according to the manufacturer's instructions, with an additional initial wash of each MinElute column with ethanol-reconstituted Qiagen Buffer AW1 (Qiagen, product number 19081) incorporated to minimize copurification of PCR inhibitors. DNA was eluted with 32 mL of Buffer AVE (Qiagen). In addition, the Taqman Exogenous Internal Positive Control Reagent (Applied Biosystems, Foster City, CA, USA) was used to control for the presence of PCR inhibitors that may have copurified with the extracted DNA; 0.4 ll 50Â Exo IPC DNA and 2 ll 10Â Exo IPC Mix (primers and probe) were added to each reaction.
JCPyV and BKPyV detection by qPCR
Quantitative PCR assays for JCPyV and BKPyV were performed on all isolated urine DNA preps, as described [21] . Details of primer sets and methods are provided the in Supplementary methods and Supplementary data, Table S1 .
Statistical analyses
Wilcoxon two-sample tests were computed to compare the distribution of continuous outcomes between CKD cases and controls. Association between categorical outcomes and CKD status was tested using Fisher's exact test when cell counts were <5 and chi-square tests when appropriate. These analyses were stratified by APOL1 genotype risk status, comparing the effects between individuals who possessed two APOL1 risk variants to those who carried none or one copy of the risk variant (Table 1) . This approach provides insight into the potential effect-modifying role that APOL1 could play on these associations. The association tests were then repeated in the combined sample (Table 2) . Logistic regressions were fitted to test for an association between JCPyV status and the presence of CKD adjusting for age and sex. Analyses were run separately for APOL1 risk genotype carriers and noncarriers and repeated in the combined data set with a formal test for interaction between APOL1 and JCPyV status. The current sample of 200 individuals was likely underpowered to detect an interaction effect between APOL1 and JCPyV. Therefore we combined this data set with a previously reported data set incorporating APOL1 genotypes and JCPyV status based on qPCR in 300 first-degree relatives of African Americans with nondiabetic CKD from NHAANS [16, 17] . Urine JCPyV was detected in 90 of 300 individuals in NHAANS with $27% of study participants meeting the definition of CKD (eGFR <60 mL/min/1.73 m 2 or UACR >30 mg/ g). The combined data set included 209 individuals who carried two APOL1 risk variants and 291 individuals with none or one risk variant. JCPyV was detected in 129 of the 500 samples for a prevalence of 25.8%. A formal interaction test was performed in this combined data set using logistic regression.
RNA fluorescence in situ hybridization (FISH) in nondiseased human kidney cryosections
Formalin-fixed paraffin-embedded (FFPE) human kidney tissue blocks were sectioned at 5 lm intervals. A JC virus type 1 oligoprobe set was custom designed by Affymetrix (Santa Clara, CA, USA) based on JC virus complementary DNA (cDNA) sequence encoding capsid protein VP1. To ensure probe specificity, blocking probes were added to mask regions with high levels of sequence identity with BKPyV and SV40 virus. The human insulin QuantiGene View RNA FISH 'double Z' type 1 oligonucleotide probe set (Affymetrix, probe ID VA1-10099) served as a negative control to ensure reliability of the presence/ absence of JCPyV RNA on human kidney and pancreas FFPE sections [22] . FISH was performed following the manufacturer's instructions.
R E S U L T S
Cases with CKD and non-CKD controls were initially evaluated based on the presence or absence of two APOL1 renal-risk variants, defining the APOL1 renal-risk genotype. Table 1 displays demographic characteristics by APOL1 renal-risk genotype and CKD case-control status. Of 39 cases with kidney disease having APOL1 risk genotypes, 17 had Stages 1-3 and 22 had Stages 4-5 CKD. Of 41 cases without APOL1 risk genotypes, 19 had Stages 1-3 and 22 had Stages 4-5 CKD. Males and females were relatively balanced between cases and controls in each genotype group. By design, controls in each APOL1 genotype group were older and had higher eGFRs and less proteinuria in order to increase the probability they would lack kidney disease as they aged. JCPyV viruria was detected significantly more often in the non-CKD controls compared with the cases with kidney disease in each APOL1 genotype group ( Because APOL1 renal-risk genotypes had no effect on the JCPyV viruria association with nephropathy protection, Table 2 displays demographic data and urine qPCR results in all 120 non-CKD controls and 80 CKD cases independent of the APOL1 genotype. JCPyV viruria was detected in 45.8% (55/ 120) of controls and 8.8% (7/80) of cases (P ¼ 3.0 x 10 À8 ). Figure 2 shows the distribution of eGFR by JCPyV status among cases and controls. The median (first quartile, third quartile) eGFR was 27.4 (9.7, 39.0) mL/min/1.73 m 2 in cases. The median (first quartile, third quartile) UPCR was 857.5 (452.0, 1811.7) mg/g in cases. Table 3 displays the results of the logistic regression in a joint analysis conducted by combining the 200 participants in the current data set with the 300 NHAANS participants analyzed previously for the effects of the APOL1 genotype on relationships with JCPyV viruria and kidney disease [16] . Significant inverse relationships between JC viruria and CKD were detected in the current sample set, the combined data sets, as well as separately in APOL1 risk genotype carriers and APOL1 nonrisk genotype carriers. Overall, African Americans with urine JCPyV had a 63% lower risk of CKD compared with those without urine JCPyV [odds ratio 0.37 (95% confidence interval 0.25-0.57); P ¼ 4.6 Â 10 À6 ]; differential relationships between JCPyV viruria and nondiabetic CKD based on APOL1 genotypes were not observed in the full sample of 500 individuals (P ¼ 0.18).
We sought to determine whether a continuous relationship between JCPyV viruria and eGFR could be detected in NHAANS participants; this analysis could not be performed in the 200 BSF cases and controls because they were selected based on eGFR. Among the 90 (of 300) NHAANS participants testing positive for JCPyV, a trend for a positive association between JCPyV viral load and eGFR was detected after adjusting for age and sex, but the correlation did not achieve statistical significance (b ¼ 3.3, SE ¼ 1.96; P ¼ 0.09). JCPyV viruria in healthy individuals is presumed to reflect virus replication in the kidney [23, 24] . RNA FISH on FFPE kidney sections in these individuals confirmed the presence of JCPyV mRNA (Figure 3 ). The absence of human insulin (INS) mRNA on renal FFPE sections served as a negative control and ensured the specificity of the JCPyV FISH probe set (Supplementary data, Figures S1 and S2 ).
D I S C U S S I O N
Viral infections are well-recognized triggers for the development of CKD; [12, 14] renal reservoirs of infection and the urine virome are likely to influence this risk in both positive and negative directions. The current study provides validation of an inverse association between urinary detection of JCPyV and CKD in African Americans without diabetes, extending this observation to African Americans with non-APOL1-associated forms of kidney disease. Only 8.8% of 80 cases with CKD in this study had JCPyV in their urine, in contrast to 45.8% of the 120 non-CKD controls. The current findings were further strengthened when considered in concert with data from the previously described NHAANS, in which a protective interaction was noted between urine JCPyV and APOL1-associated risk for CKD in 300 first-degree relatives of African Americans with nondiabetic ESKD. The combined analysis in all 500 African Americans from the present BSF and prior NHAANS report revealed that individuals with urine JCPyV had a 63% lower risk of CKD compared with those without urine JCPyV; a result that was independent from the APOL1 genotype. These 500 BSF and NHAANS participants were likely immunocompetent; individuals who received prior immunosuppressive therapy or a kidney transplant were excluded. However, it is possible that the effects of hypertension and lipid-lowering therapies could have impacted immune function and/or risk for viral replication.
The present findings are consistent with the more frequent detection of JCPyV viruria in the Brazilian general population without CKD compared to those with ESKD [18] . It is possible that loss of nephron mass in the Brazilian cases with advanced CKD could have decreased the number of cells in which the virus can replicate. However, we consider this unlikely to fully explain results in the present analysis, because cases of CKD with less severe renal impairment (median eGFR in CKD cases was 27.4 mL/min/1.73 m 2 ) were included and based on similar results in the NHAANS where the median eGFR in participants without and with APOL1 risk genotypes was 83.6 and 93 mL/ min/1.73 m 2 , respectively, and no participant had ESKD [16, 17] . JCPyV viruria has also been associated with lower rates of acute rejection after kidney transplantation in patients with preserved kidney function [25, 26] .
Both JCPyV and BKPyV appear to establish nonpathogenic latent or persistent infection in the kidney with periodic reactivation and high levels of virus excretion in the urine [27] . The prevalence of JCPyV in the urine of non-CKD controls in this study is within the reported range for healthy individuals in other reports [23, 24] . Thus the striking result is the low prevalence of JCPyV viruria in individuals with kidney disease. Fundamental differences exist between BKPyV and JCPyV biology, many of which are unexplained. JCPyV replication in the kidney has not been reported to correlate with immune dysfunction, as opposed to the well-described correlation between BKPyV activity and the degree of immunosuppression in patients on immunosuppressive therapy after transplantation [28] . Clinical manifestations associated with viral reactivation also differ; JCPyV activation can cause demyelinating neurologic disease, whereas there are only scattered reports of BKPyV-associated neurological infection [29, 30] . BKPyV nephropathy is a well-defined entity, while pathogenic effects of JCPyV in the kidneys are rare causes of nephropathy or posttransplant kidney dysfunction [31] . As mentioned above, kidney transplant recipients with JCPyV viruria had lower rates of acute rejection and better allograft survival [25, 26] .
As is the case for all cross-sectional observational studies, the current study cannot establish a cause-and-effect relationship to account for the inverse association between JCPyV viruria and kidney disease. Several potential mechanisms are possible and should be explored. First, CKD could be associated with decreased production of factors required to promote JCPyV reactivation or enhanced production of factors that are inhibitory to JCPyV reactivation or spread. Given the known roles for inflammation and inflammatory pathways on kidney disease progression [32] , the case of renal inflammation simultaneously inhibiting JCPyV replication and causing progression of CKD is attractive. A second potential mechanism is that JCPyV viruria could be a marker of other factors affecting the likelihood of renal injury. For example, according to this formulation, diminished JCPyV could serve as a marker indicating a more robust state of immune and inflammatory activation, contributing simultaneously to kidney injury and to containment of JCPyV viruria. On the other hand, enhanced JCPyV viruria could be a marker of subtle reductions in host renal immune activation and injury (this is to be contrasted with the rare reported cases in severely immunocompromised patients in which JCPyV is itself directly nephropathic) [33, 34] . This is appealing, given the important role of inflammation in non-APOL1-associated etiologies of CKD, as well as the recognized upregulation of APOL1 gene expression by inflammation with enhanced cellular toxicity [35] [36] [37] . Another potential explanation to account for the results reported here is the possibility that JCPyV reactivation inhibits replication of other viruses in the kidney that are responsible for initiating kidney disease. HIV infection is a powerful environmental trigger for APOL1-associated nephropathy (gene Â environment interaction). HIV infection causes focal segmental glomerulosclerosis, collapsing variant or HIVAN, in untreated or undertreated patients possessing two APOL1 renal-risk variants. Given the high odds ratios for APOL1 risk variant association with HIVAN [4, 38] , it would be interesting to determine whether the protective association of JCPyV reactivation extends to this APOL1-associated kidney disease. We note that 115 of the 200 BSF participants underwent next-generation sequencing of urine; none were found to harbor HIV or hepatitis C virus.
The current report is novel and contains carefully phenotyped participants, precise methodologies for urinary viral detection and viral localization studies in human kidney. However, we have not yet assessed JCPyV viruria in nonAfrican American populations or patients with diabetesassociated kidney disease. Those analyses will determine whether the current findings can be generalized beyond nondiabetic etiologies of CKD. Another potential limitation is that viral serologies were not examined. Approximately 80% of humans show serologic evidence of prior infection with JCPyV and BKPyV (likely in childhood), while the focus of this report is current viral replication and its relation to nondiabetic CKD. We ruled out the possibility that PCR amplification for viral detection had systematic differential sensitivity in the DNA preparations from cases with CKD compared with healthy controls in this report. RNA FISH showed that viral RNA was localized to kidney tissue; however, future studies are needed to assess the likely source of viral antigen in the cytoplasm of kidney cells, whether from phagocytosis of cellular debris in infected cells by macrophages or other phagocytic cells. We note the consistent finding of a markedly lower prevalence of JCPyV in the urine of CKD cases versus controls from four reports, particularly cases with milder forms of kidney disease as in the present study.
In conclusion, this study confirms and extends the inverse association between urine JCPyV, reflecting active JCPyV kidney and/or urinary tract infection, with nondiabetic nephropathy in African Americans. This association exists in cases with and without APOL1-mediated risk for nephropathy. The mechanism of protective association may include an altered host immune response with reduced inflammation and a lack of clearing persistent JCPyV from the kidneys/urinary tract or enhanced production of factors that are inhibitory to JCPyV reactivation and/or spread and concomitantly produce renal injury. These results support the performance of studies to investigate host susceptibility to viral infections and coincident predisposition to (or protection from) renal injury. 
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